Chemistry:Pateclizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | lymphotoxin alpha |
| Clinical data | |
| Other names | MLTA3698A |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6436H9910N1710O2004S44 |
| Molar mass | 144716.68 g·mol−1 |
  (what is this?) (verify) | |
Pateclizumab (MLTA3698A) is an immunomodulator. It binds to lymphotoxin alpha.[1][2][3][4][5][6]
This drug was developed by Genentech/Roche.
References
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105". WHO Drug Information 25 (2). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf.[|permanent dead link|dead link}}]
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab, American Medical Association.
- ↑ "Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)". Arthritis Res. Ther. 16 (5): 467. October 2014. doi:10.1186/s13075-014-0467-3. PMID 25359150.
- ↑ "Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial". Arthritis Res. Ther. 14 (1): R6. January 2012. doi:10.1186/ar3554. PMID 22225620.
- ↑ "Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates". Reprod. Toxicol. 63: 82–95. August 2016. doi:10.1016/j.reprotox.2016.05.014. PMID 27211603.
- ↑ "The role of lymphotoxin-α in rheumatoid arthritis". Inflamm. Res. 67 (6): 495–501. June 2018. doi:10.1007/s00011-018-1139-6. PMID 29541795.
 |  |
